Bovine Colostrum in Prevention of Necrotizing Enterocolitis and Sepsis in Very Low Birth Weight Neonates: A Randomized, Double-blind, Placebo-controlled Pilot Trial.

Abstract

Listen

Translate article

To study the efficacy of bovine colostrum in prevention of necrotizing enterocolitis (NEC) and sepsis in very low birth weight (VLBW) infants. Randomized, double-blind, placebo-controlled pilot trial. Neonates with birth weight ≤1500 g, gestation ≤32 weeks and postnatal age ≤96 h. Enteral bovine colostrum or placebo, four times a day, till 21 days of life or discharge or death. Definite NEC. Secondary outcomes included sepsis, mortality and stool interleukin-6 (IL-6) levels. Of the total 86 subjects (43 in each group), there were no statistically significant in the main outcome measures. In the colostrum group, there were trends toward higher stool IL-6 values and higher incidence of ileus and radiological signs of NEC. The use of prophylactic enteral bovine colostrum in VLBW infants shows a trend toward increased stool IL-6 and features of NEC. We were unable to detect clinical benefits.